Utopia

What Utopia does

Utopia SIS S.p.A. (Utopia Società di Investimento Semplice) is an Italian venture capital vehicle founded in 2021 and headquartered in Bologna, operating under the subsidized SIS regime with a capped net-asset ceiling of €50 million and no financial leverage. The firm executes Seed and Series A investments exclusively in the Italian Life Sciences sector, targeting four vertical focus areas: disease-modifying drugs, cross-border applications of artificial intelligence in healthcare, medical devices, and diagnostic tools and biomarkers. It is registered as number 45 in the Italian Albo delle SICAF under Article 35 of the TUF and is promoted by Fondazione Golinelli (Bologna-based philanthropic foundation operating G-Factor accelerator), Fondazione Sardegna (Sardinian regional foundation), and Executive Vice President Antonio Falcone, who previously built the largest Italian Healthcare VC fund (over €200 million in assets) at Principia SGR.

Utopia has deployed capital across six portfolio companies as of late 2023: Novavido (polymeric retinal prostheses, €1.4M), Lighthouse Biotech (liquid biopsy, €1.4M, co-invested with Pariter Partners), PerFormS (psoriasis nanotech, €0.8M), T-One Therapeutics (LINE1 immunotherapy, €2.5M), Drug Discovery & Clinic (HDHODH inhibitors for leukemia/breast cancer, €1.5M), and CaSRevolution (Alzheimer's CaSR receptor, €1.5M combined via crowdfunding with CrowdFundMe). All investments are supported by an 80% guarantee from Medio Credito Centrale, making Utopia the first Italian VC to access this guarantee instrument.

The business model is investment-return-driven rather than fee-driven: Utopia generates returns through equity appreciation and exit events (M&A, licensing, IPO) from portfolio companies, with investor tax benefits (30% deduction for IRPEF/IRES investors, capital gains exemption until end-2025) serving as the primary distribution mechanism to attract LP capital. The firm's differentiation rests on a smart-money thesis combining scientific expertise (Scientific Venture Partner Sergio Abrignani and Scientific Advisory Board including Abrignani, Ballabio, Lanzavecchia, Pelicci) with deep ties to Italian academic spin-off pipelines. Distribution occurs through direct investments, co-investment partnerships (Pariter Partners), and crowdfunding platforms (CrowdFundMe); marketing relies on LinkedIn, the company website, industry events, and Italian financial media coverage.

Name

Utopia

Legal name

UTOPIA SOCIETA' DI INVESTIMENTO SEMPLICE S.p.A.

Website

https://utopiasis.it

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

Utopia SIS is a Bologna-based Italian venture capital firm executing Seed and Series A investments in early-stage Life Sciences startups, backed by Fondazione Golinelli and Fondazione Sardegna, with a portfolio of six biotech companies and 80% Medio Credito Centrale investment guarantee coverage.

Ownership category

akta.pro rank

Product category

Venture Capital - Life Sciences

NAICS

Portfolio Management and Investment Advice (523940), Portfolio Management and Investment Advice (52394), Other Financial Vehicles (525990)

SIC

Investment Advice (6282), Investors, Nec (6799)

akta.pro industry

PRIMARYFSANALAG

Micro-PE / Lower Middle Market ETA Funds

Financial & Insurance/Private Equity & Venture Capital/Search Funds / Entrepreneurship Through Acquisition (ETA)

SECONDARYFSAEALAC

Venture Capital Fundraising Placement

Financial & Insurance/Financial Advisory, Brokerage & Intermediation/Placement Agents & Capital Raising Intermediation

Keywords

• Venture capital
• Life sciences investing
• Seed stage funding
• Biotech investments
• Healthcare venture capital

Headquarters

HQ city

Bologna

HQ country

Italy

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Investment Returns: Utopia generates returns through equity appreciation and exit events from portfolio companies. As a SIS (Società di Investimento Semplice), they invest in unlisted startups and SMEs with net assets not exceeding €50 million and no financial leverage. Returns come from capital gains on exits via M&A, licensing deals, or IPOs of portfolio companies.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Utopia is a specialized Italian venture capital firm (Società di Investimento Semplice, registered as SICAF No. 45 under Art. 35 TUF) that invests in Seed and Series A rounds of Life Sciences startups, with equity checks ranging from approximately €700,000 to €2.5 million. The firm allocates capital across four verticals — Disease Modifying Drugs, Cross-Border AI in Healthcare, Medical Devices, and Diagnostic Tools & Biomarkers — and combines financial investment with "smart money" scientific expertise delivered through a Scientific Venture Partner and Scientific Advisory Board. Investments are typically underwritten with an 80% guarantee from Medio Credito Centrale, reducing investor risk.

Product overview

Utopia is a Venture Capital investment company (Società di Investimento Semplice) that operates as a specialized investment vehicle targeting Seed and Series A stage companies in the Life Sciences sector across Italy. The company provides investment capital combined with expertise ('smart money') to high-growth startups developing innovative therapies, medical devices, and diagnostic tools. The investment strategy covers four main focus areas: Disease Modifying Drugs, Medical Devices, Cross-Border with Artificial Intelligence, and Diagnostic Tools and Biomarkers. All investments are made in unlisted startups and SMEs with 80% guarantee coverage from Medio Credito Centrale.

Differentiator

Problem solved

Functional benefit

Products and services

• Utopia SIS (Società di Investimento Semplice) A specialized Italian venture capital vehicle — registered as SICAF No. 45 under Article 35 of the TUF — that invests Seed and Series A capital into Italian Life Sciences startups. Open to qualifying IRPEF and IRES investors, it offers a 30% tax deduction plus an 80% guarantee on underlying investments through Medio Credito Centrale, and targets four verticals: Disease Modifying Drugs, Medical Devices, Cross-Border AI in Healthcare, and Diagnostic Tools & Biomarkers.
• Investment Management Services in Life Sciences Financial investment management services targeting unlisted startups and SMEs in healthcare, biomedical, and life sciences, with expertise across disease-modifying drugs, medical devices, diagnostic tools, AI in healthcare, and biomarkers. Includes scientific vetting, deal structuring, and active portfolio support delivered by in-house executives and the Scientific Advisory Board.

Quantifiable outcome

• 80% investment guarantee from Medio Credito Centrale
• +1 more outcomes

Named customers6 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Three partnerships are on record, tiered major.

• CrowdFundMe SpAmajorChannel Partner/ Reseller/ Distributor · 1 November 2023Crowdinvesting portal listed on Italian Stock Exchange. Launched collaboration with Utopia for CaSRevolution's capital raise via equity crowdfunding. CrowdFundMe hosts the campaign while Utopia acts as lead investor. First experiment of new structural investment strategy.
• Italian Institute of Technology (IIT)majorStrategic or Co-development Partner · 1 January 2021Research institution whose projects have led to portfolio investments. Novavido originated from IIT research (10 years of development) on polymeric retinal prostheses. IIT provides scientific foundation for startups and technology transfer support.
• G-Factor (Golinelli Foundation Accelerator)majorStrategic or Co-development Partner · 1 January 2021Accelerator and venture builder controlled by Fondazione Golinelli. Several portfolio companies (Novavido, PerFormS) were accelerated through G-Factor. Provides incubation services, mentorship, and connection to the Golinelli ecosystem.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Market position

Strengths4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/utopiasis

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Utopia